After the close, Theravance, Inc. (NASDAQ: THRX) announced the record date of May 15, 2014 for the Company’s strategic separation into two independent, publicly traded companies via a stock dividend. Theravance Inc. (NASDAQ:THRX) shares after opening at $26.74 moved to $27.15 on last trade day and at the end of the day closed at $27.13. Company price to sales ratio in past twelve months was calculated as 636.20 and price to cash ratio as 6.57. Theravance Inc. (NASDAQ:THRX) showed a positive weekly performance of 0.78%.
Net income attributable to Intrexon Corp (NYSE:XON) of $4.1 million, or $0.04 per common share, for the quarter ended March 31, 2014 compared to net loss attributable to Intrexon of $36.3 million for the quarter ended March 31, 2013. Intrexon Corp (NYSE:XON) shares fell -11.14% in last trading session and ended the day on $15.39. IXON return on assets is -28.10%.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on 6 may announced its first quarter 2014 financial results and ongoing progress with IPI-145, the company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved down -2.54% in last trading session and was closed at $8.82, while trading in range of $8.40 – $9.44. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date (YTD) performance is -36.13%.
ImmunoGen Inc. (NASDAQ:IMGN) reported third quarter fiscal 2014 (ending Mar 31, 2014) loss of 29 cents per share, excluding a non-cash expense related to the company’s collaboration with CytomX. The company’s loss was at par with the Zacks Consensus Estimate but wider than the year-ago loss of 2 cents per share. ImmunoGen, Inc. (NASDAQ:IMGN) weekly performance is -11.05%. On last trading day company shares ended up $11.51. ImmunoGen, Inc. (NASDAQ:IMGN) distance from 50-day simple moving average (SMA50) is -21.95%. Analysts mean target price for the company is $17.29.
Leave a Reply